HK1203847A1 - Fixed dose combination therapy of parkinsons disease - Google Patents

Fixed dose combination therapy of parkinsons disease

Info

Publication number
HK1203847A1
HK1203847A1 HK15104685.5A HK15104685A HK1203847A1 HK 1203847 A1 HK1203847 A1 HK 1203847A1 HK 15104685 A HK15104685 A HK 15104685A HK 1203847 A1 HK1203847 A1 HK 1203847A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
fixed dose
dose combination
parkinsons disease
parkinsons
Prior art date
Application number
HK15104685.5A
Other languages
English (en)
Chinese (zh)
Inventor
Nurit Livnah
Pninit Litman
Sarit Zaksh
Original Assignee
Pharma Two B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48781101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1203847(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Two B Ltd filed Critical Pharma Two B Ltd
Publication of HK1203847A1 publication Critical patent/HK1203847A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15104685.5A 2012-01-12 2015-05-18 Fixed dose combination therapy of parkinsons disease HK1203847A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585824P 2012-01-12 2012-01-12
PCT/IL2013/050025 WO2013105092A1 (en) 2012-01-12 2013-01-10 Fixed dose combination therapy of parkinson's disease

Publications (1)

Publication Number Publication Date
HK1203847A1 true HK1203847A1 (en) 2015-11-06

Family

ID=48781101

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104685.5A HK1203847A1 (en) 2012-01-12 2015-05-18 Fixed dose combination therapy of parkinsons disease

Country Status (22)

Country Link
US (1) US20150079187A1 (ru)
EP (1) EP2802319B1 (ru)
JP (1) JP6243351B2 (ru)
KR (2) KR102276896B1 (ru)
CN (1) CN104168896B (ru)
AU (1) AU2013208653B2 (ru)
CA (1) CA2860952C (ru)
CY (1) CY1119793T1 (ru)
DK (1) DK2802319T3 (ru)
ES (1) ES2655676T3 (ru)
HK (1) HK1203847A1 (ru)
HU (1) HUE038029T2 (ru)
IL (1) IL233572B (ru)
IN (1) IN2014MN01568A (ru)
LT (1) LT2802319T (ru)
MX (1) MX360409B (ru)
NO (2) NO2802319T3 (ru)
PL (1) PL2802319T3 (ru)
PT (1) PT2802319T (ru)
RS (1) RS56742B1 (ru)
RU (1) RU2642962C9 (ru)
WO (1) WO2013105092A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104367565A (zh) * 2014-11-21 2015-02-25 哈尔滨圣吉药业股份有限公司 一种盐酸普拉克索缓释微丸
CN105147627B (zh) * 2015-08-19 2019-04-12 天津红日药业股份有限公司 一种含有盐酸普拉克索的药物组合物及其制备方法
WO2019036624A1 (en) * 2017-08-17 2019-02-21 Gu Zi Qiang MONOAMINE PAMOATE SALT TYPE ANTI-PARKINSON AGENTS, PROCESS FOR PREPARING AND USING SAME
CA3122935A1 (en) * 2018-12-19 2020-06-25 Galecto Biotech Ab Amorphous form and process
JP2023504876A (ja) * 2019-12-06 2023-02-07 シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド 薬物組成物、キット及びその応用
WO2023112024A1 (en) * 2021-12-14 2023-06-22 Pharma Two B Ltd. Method of treating parkinson's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173426A1 (en) * 2002-02-25 2017-05-31 Biogen MA Inc. Administration of agents for the treatment of inflammation
JP2007518754A (ja) * 2004-01-22 2007-07-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング モノアミン神経伝達物質再取込みインヒビターとドーパミンアゴニストを含む医薬組成物
US20090017015A1 (en) * 2004-02-20 2009-01-15 Thomas Edward Hughes Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
CA2574925A1 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
CA2646250A1 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
CA2684550A1 (en) * 2007-04-24 2008-10-30 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
PL2303330T5 (pl) * 2008-06-06 2021-10-25 Pharma Two B Ltd. Kompozycje farmaceutyczne do leczenia choroby Parkinsona
JP2012500283A (ja) * 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク. (r)−プラミペキソールを使用した組成物並びにその方法
EP3517103A1 (en) * 2010-02-03 2019-07-31 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof

Also Published As

Publication number Publication date
RU2771522C2 (ru) 2022-05-05
IL233572A0 (en) 2014-08-31
CN104168896B (zh) 2018-08-10
NO2802319T3 (ru) 2018-03-24
PT2802319T (pt) 2018-01-29
HUE038029T2 (hu) 2018-09-28
CA2860952C (en) 2020-09-15
CN104168896A (zh) 2014-11-26
RS56742B1 (sr) 2018-03-30
JP6243351B2 (ja) 2017-12-06
RU2642962C2 (ru) 2018-01-29
MX2014008537A (es) 2014-11-25
CY1119793T1 (el) 2018-06-27
MX360409B (es) 2018-10-30
JP2015508411A (ja) 2015-03-19
RU2642962C9 (ru) 2018-05-04
ES2655676T3 (es) 2018-02-21
EP2802319A1 (en) 2014-11-19
KR102276896B1 (ko) 2021-07-14
EP2802319B1 (en) 2017-10-25
IL233572B (en) 2020-05-31
RU2014132940A (ru) 2016-02-27
RU2017146994A (ru) 2018-10-22
PL2802319T3 (pl) 2018-04-30
IN2014MN01568A (ru) 2015-05-08
KR20200013791A (ko) 2020-02-07
CA2860952A1 (en) 2013-07-18
LT2802319T (lt) 2018-04-10
DK2802319T3 (da) 2018-01-29
WO2013105092A1 (en) 2013-07-18
EP2802319A4 (en) 2015-07-01
NO2901008T3 (ru) 2018-08-04
AU2013208653A1 (en) 2014-08-28
AU2013208653B2 (en) 2017-04-20
RU2017146994A3 (ru) 2021-03-16
KR20140138629A (ko) 2014-12-04
US20150079187A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
HK1211475A1 (en) Combination therapy
HK1203963A1 (en) Novel therapeutic agents
IL263661A (en) Combination therapy for the treatment of glioblastoma
EP2906208A4 (en) THERAPEUTIC TREATMENT
HK1203417A1 (en) New therapeutic approaches for treating parkinsons disease
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
HK1203847A1 (en) Fixed dose combination therapy of parkinsons disease
GB201217439D0 (en) Combination therapy
GB201207305D0 (en) Therapy
HK1210426A1 (en) Combination therapy
GB201215184D0 (en) Therapeutic virus
EP2804853A4 (en) THERAPEUTIC USES
IL236873A0 (en) therapeutic compounds
GB201204645D0 (en) Treatment of disease
HUP1200364A2 (en) Therapeutic insole
ZA201405764B (en) Novel therapeutic agents
GB201214456D0 (en) Therapeutic treatments
GB201214454D0 (en) Therapeutic treatments
IL233495A0 (en) Combination for cancer treatment
GB201214985D0 (en) Modified therapeutic agents
HUP1200530A2 (en) Medical splint
GB201213712D0 (en) Modified therapeutic agents
GB201211543D0 (en) Combination therapy